Earnings Per Share
$-0.92
Step edit validates differentiation. Chief Commercial Officer Brian Powl highlighted an unusual competitive advantage: “We’re also thrilled to report that certain Blue plans are now requiring patients to go on KOMZIFTI before allowing coverage for the other approved menin inhibitor. It’s our understanding that their decision to implement this step edit was based on the efficacy, safety and predictable price per patient.”. Powl noted that 84% of private payers established coverage within 90 days of approval, surpassing internal expectations. CEO Troy Wilson emphasized the franchise’s durability: “KOMZIFTI is now listed in the FDA’s Orange book with patent protection through July 2044”.
Collaboration revenue guidance set. The company provided multi-year collaboration revenue guidance reflecting non-cash accounting recognition under its Kyowa Kirin agreement: $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028. CFO Tom Doyle stated that cash of $667.2 million as of December 31, 2025, together with anticipated milestones of $180 million from Kyowa Kirin, will fund the ziftomenib AML program through first Phase 3 topline results from the KOMET-017 frontline trial expected in 2028.
What to Watch: First-half 2026 data from the KOMET-007 intensive chemotherapy combination trial and preliminary results from the darlifarnib plus adagrasib study in KRAS G12C-mutated solid tumors will test whether Kura can expand beyond its initial relapsed/refractory AML indication into frontline disease and solid tumor markets.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
